Drug Profile
CV 7202
Alternative Names: CV-7202Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator CureVac
- Class RNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rabies
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Rabies(Prevention) in Belgium (IM)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Rabies(Prevention) in Germany (IM)
- 03 Jan 2022 CV 7202 is still in phase I trial for Rabies (Prevention) in Germany, Belgium (IM) (NCT03713086) (EudraCT 2017-002856-10) (CureVac AG pipeline, January 2022)